Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bio-Path Holdings (BPTH)

Bio-Path Holdings (BPTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,010
  • Shares Outstanding, K 2,552
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,080 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 0.22
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -6.91
  • Most Recent Earnings $-0.87 on 11/14/24
  • Next Earnings Date 11/15/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.37
  • Number of Estimates 1
  • High Estimate -0.37
  • Low Estimate -0.37
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6100 +30.98%
on 11/18/24
1.1400 -29.91%
on 10/23/24
-0.2710 (-25.33%)
since 10/21/24
3-Month
0.6100 +30.98%
on 11/18/24
1.4600 -45.27%
on 08/22/24
-0.7010 (-46.73%)
since 08/21/24
52-Week
0.6100 +30.98%
on 11/18/24
12.3660 -93.54%
on 11/30/23
-9.2010 (-92.01%)
since 11/21/23

Most Recent Stories

More News
Bio-Path Holdings, Inc. Expands DNAbilize® Technology to Obesity Treatment, Reveals Third Quarter Financial Results

Bio-Path Holdings reports Q3 2024 results, initiating obesity program, advancing oncology trials, and closing a $4M private placement.Quiver AI SummaryBio-Path Holdings, Inc. has expanded its DNAbilize®...

BPTH : 0.7990 (+1.43%)
Bio-Path: Q3 Earnings Snapshot

Bio-Path: Q3 Earnings Snapshot

BPTH : 0.7990 (+1.43%)
Bio-Path Holdings Reports Third Quarter 2024 Financial Results

BPTH : 0.7990 (+1.43%)
Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024

BPTH : 0.7990 (+1.43%)
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BPTH : 0.7990 (+1.43%)
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BPTH : 0.7990 (+1.43%)
Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity

BPTH : 0.7990 (+1.43%)
Bio-Path: Q2 Earnings Snapshot

Bio-Path: Q2 Earnings Snapshot

BPTH : 0.7990 (+1.43%)
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END

ATNM : 1.4700 (+5.76%)
BPTH : 0.7990 (+1.43%)
LGVN : 1.8700 (+1.08%)
SLS : 1.2200 (-1.61%)
BMY : 58.23 (+0.60%)
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

ATNM : 1.4700 (+5.76%)
BPTH : 0.7990 (+1.43%)
LGVN : 1.8700 (+1.08%)
SLS : 1.2200 (-1.61%)
BMY : 58.23 (+0.60%)

Business Summary

BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout...

See More

Key Turning Points

3rd Resistance Point 0.9510
2nd Resistance Point 0.8980
1st Resistance Point 0.8485
Last Price 0.7990
1st Support Level 0.7460
2nd Support Level 0.6930
3rd Support Level 0.6435

See More

52-Week High 12.3660
Fibonacci 61.8% 7.8752
Fibonacci 50% 6.4880
Fibonacci 38.2% 5.1008
Last Price 0.7990
52-Week Low 0.6100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar